PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.
A husband saw significant hair regrowth in 2.5 months using minoxidil, finasteride, collagen, biotin, multivitamins, GHK-cu, microneedling, and scalp oils. His wife highlighted the routine's effectiveness and the importance of consistency.
The user is frustrated with hair regrowth despite using finasteride, minoxidil, dutasteride, RU58841, ketoconazole shampoo, and dermastamping. Others suggest improvement, advise against overmedication, and recommend consulting a doctor or considering a simpler regimen or hair transplant.
Dutasteride is hard to get in Europe due to prescription rules, leading some to consider online pharmacies or travel. Users discuss alternatives like private doctors and compare it to finasteride, expressing concerns about side effects and effectiveness.
Switching from finasteride to dutasteride may be more effective for hair regrowth due to dutasteride's stronger enzyme inhibition, but combining both drugs could enhance results. Some users report better outcomes with dutasteride, while others recommend a gradual transition to prevent potential hair loss.
There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.
Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
A user reported significant hair improvement after one month of using dutasteride and oral minoxidil. Others expressed skepticism, attributing perceived changes to lighting and styling, and debated the effectiveness and risks of these treatments.
Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.
Many younger men are experiencing hair loss due to genetics, diet, stress, and lifestyle changes. Treatments like finasteride and minoxidil are mentioned, with some users noting improvements.
A 17-year-old experiencing hair loss is using Minoxidil but is hesitant about Finasteride due to potential side effects. Others recommend Finasteride for its effectiveness and suggest alternatives like vitamins and derma rollers.
The user recently went bald and plans to stop taking finasteride, questioning its impact on beard and eyebrow density. Responses suggest he looks good both bald and with thinning hair, with some recommending minoxidil for the crown and noting finasteride's effect on beard thickness.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
A 40+ male shared his one-year progress using minoxidil twice daily and microneedling once a week, showing significant hair improvement. He also occasionally uses finasteride in a low dosage due to side effects.
A 19-year-old is distressed about his 17-year-old autistic brother's hair loss, projecting his own insecurities despite being on finasteride and dutasteride. Replies suggest the brother might not care about balding, and the poster should address his own issues.
The conversation is about overcoming fear of finasteride/dutasteride for hair loss treatment. Users suggest starting with a small supply, noting side effects are rare and reversible, and emphasize personal comfort and confidence.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.
Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.
The post discusses the cost of oral Minoxidil and dutasteride in India. Users compare prices and share experiences with international shipping and insurance coverage for Minoxidil and finasteride.